This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Reprogram Biosciences Closes Seed Financing
Business seed financing

Reprogram Biosciences Closes Seed Financing

Analysis based on 6 articles · First reported May 27, 2026 · Last updated Jun 01, 2026

Sentiment
60
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The successful seed financing of Reprogram Biosciences indicates investor confidence in its mRNA-based oncology therapeutics, potentially boosting the biotechnology sector. This funding will enable Reprogram Biosciences to advance its lead program and AI discovery engine, which could lead to new treatments for solid tumors and create future investment opportunities.

Biotechnology Venture Capital
Event Summary

Reprogram Biosciences, a preclinical oncology biotechnology company, announced the close of its seed financing round, bringing its total capital raised to $6 million since its founding in 2025. The financing round saw participation from investors including Unshackled Ventures, 1517 Fund, and Rings of Power. The proceeds will be used to support the continued development of Reprogram Biosciences' lead program, expand its AI discovery engine called CellRecodeX, and advance CMC activities. Reprogram Biosciences is developing mRNA-based therapeutics designed to reprogram tumor cells in situ to activate the immune system, aiming to transform immunosuppressive tumor microenvironments into sites of active immune priming for systemic antitumor responses. Rustam Esanov, CEO of Reprogram Biosciences, highlighted the differentiated approach, while Colin Greenspon of Rings of Power praised the team's efficiency and the science's potential.

Entities Involved
priv
Reprogram Biosciences
Reprogram Biosciences successfully closed its seed financing round, raising $6 million to advance its mRNA-based therapeutics for solid tumors and expand its AI discovery engine.
Importance 100.0 Sentiment 70.0
per
Rustam Esanov
Rustam Esanov, CEO and co-founder of Reprogram Biosciences, articulated the differentiated approach of the company's therapeutics in reprogramming tumors for immune activation.
Importance 80.0 Sentiment 60.0
oth
Rings of Power
Rings of Power co-founder Colin Greenspon expressed strong support for Reprogram Biosciences' approach and team, highlighting their capital efficiency and the potential impact of their technology.
Importance 70.0 Sentiment 60.0
priv
Unshackled Ventures
Unshackled Ventures participated in the seed financing round for Reprogram Biosciences, investing in its innovative oncology therapeutics.
Importance 60.0 Sentiment 50.0
oth
1517 Fund
1517 Fund invested in Reprogram Biosciences' seed financing, supporting the development of its mRNA-based cancer treatments.
Importance 60.0 Sentiment 50.0
per
Colin Greenspon
Colin Greenspon, co-founder and partner at Rings of Power, praised Reprogram Biosciences' innovative approach and the efficiency of its founders.
Importance 60.0 Sentiment 50.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.